|
[1]
|
Siegel, R.L., Miller, K.D., Wagle, N.S., et al. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Oeffinger, K.C., Mertens, A.C., Sklar, C.A., et al. (2006) Chronic Health Conditions in Adult Survivors of Childhood Cancer. The New England Journal of Medicine, 355, 1572-1582. [Google Scholar] [CrossRef]
|
|
[3]
|
Chen, D.Y., Liu, J.R., Tseng, C.N., et al. (2022) Major Adverse Car-diovascular Events in Patients with Renal Cell Carcinoma Treated with Targeted Therapies. JACC: CardioOncology, 4, 223-234. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Wang, Y., Cui, C., Ren, X., et al. (2022) Cardiovascular Toxicity Associated with Angiogenesis Inhibitors: A Comprehensive Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System Database from 2014 to 2021. Frontiers in Cardiovascular Medicine, 9, Article 988013. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Lenihan, D.J., Cardinale, D. and Cipolla, C.M. (2010) The Com-pelling Need for a Cardiology and Oncology Partnership and the Birth of the International CardiOncology Society. Pro-gress in Cardiovascular Diseases, 53, 88-93. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Schlumberger, M., Tahara, M., Wirth, L.J., et al. (2015) Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. The New England Journal of Medicine, 372, 621-630. [Google Scholar] [CrossRef]
|
|
[7]
|
Hoeben, A., Landuyt, B., Highley, M.S., et al. (2004) Vascular En-dothelial Growth Factor and Angiogenesis. Pharmacological Reviews, 56, 549-580. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Folkman, J. (2002) Role of Angiogenesis in Tumor Growth and Metastasis. Seminars in Oncology, 29, 15-18. [Google Scholar] [CrossRef]
|
|
[9]
|
Vimalraj, S. (2022) A Concise Review of VEGF, PDGF, FGF, Notch, Angiopoietin, and HGF Signalling in Tumor Angiogenesis with a Focus on Alternative Approaches and Future Directions. International Journal of Biological Macromolecules, 221, 1428-1438. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Hicklin, D.J. and Ellis, L.M. (2005) Role of the Vascular En-dothelial Growth Factor Pathway in Tumor Growth and Angiogenesis. Journal of Clinical Oncology, 23, 1011-1027. [Google Scholar] [CrossRef]
|
|
[11]
|
Jang, H.J., Kim, B.J., Kim, J.H. and Kim, H.S. (2017) The Addition of Bevacizumab in the First-Line Treatment for Metastatic Colorectal Cancer: An Updated Meta-Analysis of Randomized Trials. Oncotarget, 8, 73009-73016. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Li, Y., Wang, W., Gao, R., Xu, X.M. and Zhang, Y. (2021) Ge-nome-Wide Prioritization Reveals Novel Gene Signatures Associated with Cardiotoxic Effects of Tyrosine Kinase Inhib-itors. Oncology Letters, 21, Article No. 94. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Du, Z. and Lovly, C.M. (2018) Mechanisms of Receptor Tyrosine Ki-nase Activation in Cancer. Molecular Cancer, 17, Article No. 58. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Chaar, M., Kamta, J. and Ait-Oudhia, S. (2018) Mechanisms, Monitoring, and Management of Tyrosine Kinase Inhibitors-Associated Cardiovascular Toxicities. OncoTargets and Therapy, 11, 6227-6237. [Google Scholar] [CrossRef]
|
|
[15]
|
Force, T., Krause, D.S. and Van Etten, R.A. (2007) Molecular Mecha-nisms of Cardiotoxicity of Tyrosine Kinase Inhibition. Nature Reviews Cancer, 7, 332-344. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Zamorano, J.L., Lancellotti, P., Rodriguez Muñoz, D., et al. (2016) 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed under the Auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC). European Heart Journal, 37, 2768-2801. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Kamba, T. and Mcdonald, D.M. (2007) Mechanisms of Adverse Effects of Anti-VEGF Therapy for Cancer. British Journal of Cancer, 96, 1788-1795. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Zhao, T., Wang, X., Xu, T., Xu, X.D. and Liu, Z.H. (2017) Bevacizumab Significantly Increases the Risks of Hypertension and Proteinuria in Cancer Patients: A Sys-tematic Review and Comprehensive Meta-Analysis. Oncotarget, 8, 51492-51506. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Hamnvik, O.P., Choueiri, T.K., Turchin, A., et al. (2015) Clinical Risk Factors for the Development of Hypertension in Patients Treated with Inhibitors of the VEGF Signaling Pathway. Cancer, 121, 311-319. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Totzeck, M., Mincu, R.I. and Rassaf, T. (2017) Cardiovascular Adverse Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis of More than 20 000 Patients. Journal of the American Heart Association, 6, e006278. [Google Scholar] [CrossRef]
|
|
[21]
|
Haroon, Z.A., Amin, K., Saito, W., et al. (2002) SU5416 Delays Wound Healing through Inhibition of TGF-β 1 Activation. Cancer Biology & Therapy, 1, 121-126. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Richards, C.J., Je, Y., Schutz, F.A., et al. (2011) Incidence and Risk of Conges-tive Heart Failure in Patients with Renal and Nonrenal Cell Carcinoma Treated with Sunitinib. Journal of Clinical Oncol-ogy, 29, 3450-3456. [Google Scholar] [CrossRef]
|
|
[23]
|
Chintalgattu, V., Ai, D., Langley, R.R., et al. (2010) Cardiomyo-cyte PDGFR-β Signaling Is an Essential Component of the Mouse Cardiac Response to Load-Induced Stress. The Jour-nal of Clinical Investigation, 120, 472-484. [Google Scholar] [CrossRef]
|
|
[24]
|
Vallerio, P., Orenti, A., Tosi, F., et al. (2022) Major Adverse Cardiovascu-lar Events Associated with VEGF-Targeted Anticancer Tyrosine Kinase Inhibitors: A Real-Life Study and Proposed Al-gorithm for Proactive Management. ESMO Open, 7, Article ID: 100338. [Google Scholar] [CrossRef] [PubMed]
|